An Evaluation of the Safety of Escalating Doses of Tc 99m Tilmanocept by Intravenous (IV) Injection in Human Immunodeficiency Virus (HIV) Subjects Diagnosed With Kaposi Sarcoma (KS)
Not yet recruiting
Phase of Trial: Phase 0
Latest Information Update: 18 Jul 2017
At a glance
- Drugs Tc 99m tilmanocept (Primary)
- Indications Kaposi's sarcoma
- Focus Adverse reactions
- Sponsors Navidea Biopharmaceuticals
- 10 Jul 2017 Planned number of patients changed from 16 to 24.
- 10 Jul 2017 Planned End Date changed from 31 Mar 2018 to 31 Oct 2018.
- 10 Jul 2017 Planned primary completion date changed from 31 Jan 2018 to 31 Aug 2018.